Research ArticleResearchMedication SafetyPatient Education

Prompt oseltamivir was associated with fewer hospital and ICU admissions in veterans

Open forum infectious diseases (PubMed)Aug 24, 2026

AI-summarized from the linked source. Educational brief, not medical advice.

Brief summary

In a target-trial emulation of veterans with test-confirmed outpatient influenza, oseltamivir treatment within six hours of a positive test was associated with lower 10-day hospitalization and ICU admission, but not lower 30-day mortality.

What NurseJet pulled from the source

The analysis included 28,920 veterans; 87% were men and the median age was 61 years. Weighted hospitalization risk was 3.81% with oseltamivir versus 6.96% without antiviral treatment, and ICU admission was 0.65% versus 1.38%. Mortality was similar, and the observational design cannot eliminate residual confounding.

Why this matters for nurses

Emergency, geriatric, and infection-prevention nurses help move patients from testing to treatment while identifying deterioration and barriers to medication access. The study supports timely workflow attention but does not prove that oseltamivir alone caused the observed reduction in admissions.

Bedside takeaway

Move confirmed influenza results into the approved antiviral pathway promptly while continuing careful assessment for severe illness.

How This Applies in Practice

Use this when: Caring for an outpatient or emergency patient with a newly positive influenza test who may be eligible for antiviral treatment.

On your shift

Communicate the positive result and symptom timeline promptly and complete the approved antiviral eligibility workflow.
Before administration or teaching, verify the prescription, renal dosing considerations, allergies, and medication access plan.
Provide adherence and return-precaution education and escalate respiratory compromise, dehydration, altered mentation, or other severe features.

Keep in mind: The association comes from an observational emulation in veterans and does not establish benefit for every patient. Follow local protocol and provider orders.

Key takeaways

The target-trial emulation included 28,920 veterans with influenza diagnosed in Veterans Health Administration emergency departments.
Oseltamivir treatment within six hours of a positive test was associated with lower 10-day hospitalization risk.
ICU admission was also less frequent in the treated group, while 30-day mortality was similar.
The largest absolute hospitalization-risk reductions were observed in adults aged 65 years or older and when treatment was prescribed within three hours of diagnosis.

Practice implications

For a patient with confirmed influenza, communicate the result promptly, complete ordered antiviral screening and administration without avoidable delay, and reinforce dosing and return precautions. Escalate respiratory compromise or other signs of severe illness immediately.

Limitations & cautions

This was an observational target-trial emulation rather than a randomized trial, so residual confounding is possible. The cohort was predominantly male and drawn from the Veterans Health Administration, limiting generalizability; mortality did not differ between groups.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations

Exact source links

Open source

Public citations are filtered to exact credible source pages. Homepage-only or invalid links stay in admin review and are not shown here.

Open forum infectious diseases (PubMed)

Open forum infectious diseases (PubMed). Oseltamivir for Treatment of Influenza Among Outpatient Veterans: Target Trial Emulation.

Open original source

https://pubmed.ncbi.nlm.nih.gov/42639473/

Professional education only

This summary does not replace clinical judgment, facility policy, provider orders, or official guidelines. Verify practice changes against the original source and local protocol.

Related briefs

More updates for this clinical area

Back to Discover

Renal failure (PubMed)Sep 7, 2026Research Article

A single-center retrospective cohort found that approximately one quarter of laboratory-defined acute kidney injury cases on internal medicine wards were not documented, particularly when maximal creatinine was lower.

Med-SurgAI summaryReview source

Research ArticleResearchQuality ImprovementAI summary · original source linked below

Among 161 adult hospitalizations meeting serum-creatinine criteria for acute kidney injury, 39 cases (24.2%) were undocumented. Length of stay and in-hospital mortality did not differ significantly by documentation status.

Key takeaways

In the 149 hospitalizations with a demonstrable creatinine change, 33 cases (22.1%) were undocumented.
Higher maximal creatinine was associated with lower adjusted odds of underdocumentation.
The study did not test whether a detection or documentation intervention improves care or outcomes.

Why this matters on shift

A smaller creatinine rise may receive less attention even when it meets the study's laboratory definition of acute kidney injury, which can affect how renal risk is communicated across the inpatient team.

Bedside takeaway

Trend ordered renal-function results and communicate clinically important changes through local escalation and documentation workflows.

Nursing implications

Trend ordered renal-function results and communicate clinically important changes through the care team according to local escalation and documentation workflows.

Limitations & cautions

Abstract-only summary. This was a retrospective, single-center study of 161 hospitalizations; urine-output criteria and reliable preadmission creatinine values were unavailable, and the reference creatinine method may affect case classification.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations · exact source links

Renal failure (PubMed). Underdocumentation of laboratory-defined acute kidney injury in internal medicine wards: a retrospective cohort study.

Open original sourceFull brief

AI-summarized from the linked source. Review the original article before applying to practice.

Pediatric emergency care (PubMed)Sep 7, 2026Research Article

A double-blind randomized trial found no reduction in vomiting or faster oral tolerance with intravenous pantoprazole versus placebo in children with acute gastroenteritis and persistent vomiting after ondansetron.

Peds EmergencyAI summaryReview source

Research ArticleResearchMedication SafetyAI summary · original source linked below

The trial randomized 100 children. Vomiting episodes and oral tolerance at 6 and 12 hours did not differ significantly, while median hospital stay was 2 days with pantoprazole and 1 day with placebo.

Key takeaways

The median participant age was 14 months, and 67% of participants were male.
Oral tolerance at 12 hours was 86% in both groups.
The longer stay associated with pantoprazole requires cautious interpretation because this was a single-center trial.

Why this matters on shift

The trial does not support empiric intravenous proton-pump inhibition for persistent vomiting in pediatric acute gastroenteritis after ondansetron.

Bedside takeaway

Clarify the indication for empiric acid suppression and keep hydration and oral-tolerance assessment central to care.

Nursing implications

Prioritize the ordered hydration and oral-tolerance plan, document ongoing emesis, and clarify the indication before administering empiric acid suppression.

Limitations & cautions

Abstract-only summary. This was a single-center study of 100 children in Tehran, and the abstract does not describe adverse events or explain why hospitalization was longer in the pantoprazole group.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations · exact source links

Pediatric emergency care (PubMed). Effect of Intravenous Pantoprazole on Clinical Outcomes in Pediatric Acute Gastroenteritis: A Placebo-Controlled RCT.

Open original sourceFull brief

AI-summarized from the linked source. Review the original article before applying to practice.

European heart journal (PubMed)Sep 6, 2026Research Article

In the pragmatic TARGET-D randomized trial, vitamin D dosing titrated to a serum target did not significantly reduce the composite of death, recurrent myocardial infarction, heart-failure hospitalization, or stroke after myocardial infarction.

Telemetry Med-SurgAI summaryReview source

Research ArticleResearchMedication SafetyPatient EducationAI summary · original source linked below

Among 630 participants followed for an average of 4.2 years, major cardiovascular events occurred in 15.7% with targeted vitamin D management and 18.4% with usual care (hazard ratio 0.85, 95% CI 0.58 to 1.24; P=0.40).

Key takeaways

At baseline, 87% of participants had a 25-hydroxyvitamin D level of 40 ng/mL or lower.
The primary composite outcome and the individual outcomes of death, heart-failure hospitalization, and stroke were not significantly different.
A lower recurrent-MI rate was a secondary finding and should not override the nonsignificant primary result.

Why this matters on shift

The trial cautions against presenting targeted vitamin D supplementation as a proven strategy for reducing major cardiovascular events after myocardial infarction.

Bedside takeaway

Present vitamin D as prescribed supplementation, not as a replacement for established post-MI secondary prevention.

Nursing implications

Reinforce the prescribed secondary-prevention plan and avoid implying that vitamin D replaces therapies with established post-MI benefit.

Limitations & cautions

Abstract-only summary. The trial included 630 participants, 78.1% were men, the primary confidence interval included benefit and no benefit, and individual secondary outcomes were not the primary endpoint.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations · exact source links

European heart journal (PubMed). Targeted vitamin D supplementation and major adverse cardiovascular events after myocardial infarction: the TARGET-D trial.

Open original sourceFull brief

AI-summarized from the linked source. Review the original article before applying to practice.

How This Applies in Practice

Key takeaways

Practice implications

Limitations & cautions

Exact source links

More updates for this clinical area

One in four laboratory-defined AKI cases went undocumented on medicine wards

IV pantoprazole did not improve vomiting or oral tolerance in pediatric gastroenteritis

Targeted vitamin D did not significantly reduce major cardiovascular events after MI